Incyte (NASDAQ:INCY) Receives “Hold” Rating from Truist Financial
Truist Financial reiterated their hold rating on shares of Incyte (NASDAQ:INCY – Free Report) in a research note released on Wednesday morning, Marketbeat.com reports. Truist Financial currently has a $74.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $83.00. Several other research firms have also recently weighed in on […]
21 Sep 08:09 · The Markets Daily